Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.

MedStar author(s):
Citation: American Journal of Obstetrics & Gynecology. 207(5):398.e1-8, 2012 Nov.PMID: 22967833Institution: MedStar Health Research InstituteForm of publication: Journal ArticleMedline article type(s): Clinical Trial | Journal Article | Research Support, N.I.H., ExtramuralSubject headings: *Hydroxyprogesterones/pk [Pharmacokinetics] | *Placenta/me [Metabolism] | *Progestins/pk [Pharmacokinetics] | Adult | Biological Transport/ph [Physiology] | Body Mass Index | Female | Fetal Blood/ch [Chemistry] | Humans | Hydroxyprogesterones/bl [Blood] | Hydroxyprogesterones/pd [Pharmacology] | Pregnancy | Progestins/bl [Blood] | Progestins/pd [Pharmacology] | Young AdultLocal holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006ISSN:
  • 0002-9378
Name of journal: American journal of obstetrics and gynecologyAbstract: CONCLUSION: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier. Copyright 2012 Mosby, Inc. All rights reserved.OBJECTIVE: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation.RESULTS: The half-life (median +/- SD) of 17-OHPC was 16.2 +/- 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection.STUDY DESIGN: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery.All authors: Benedetti T, Caritis SN, Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetrical-Fetal Pharmacology Research Units Network, Fischer D, Hankins GD, Hebert MF, Jackson A, Mattison D, Miodovnik M, Sharma S, Umans JG, Venkataramanan R, Zajicek ADigital Object Identifier: Date added to catalog: 2013-09-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 22967833

Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006

CONCLUSION: The apparent half-life of 17-OHPC is long, and pharmacokinetic parameters vary widely between subjects and are affected by maternal body mass index. The drug crosses the placental barrier. Copyright 2012 Mosby, Inc. All rights reserved.

OBJECTIVE: The purpose of this study was to estimate pharmacokinetic parameters and to evaluate placental transport of 17-hydroxyprogesterone caproate (17-OHPC) in singleton gestation.

RESULTS: The half-life (median +/- SD) of 17-OHPC was 16.2 +/- 6 days. Concentrations of 17-OHPC were higher during study 2 than during study 1. Body mass index affected maternal 17-OHPC concentrations. Cord:maternal 17-OHPC concentration ratios averaged 0.2; 17-OHPC was detectible in cord plasma 44 days after the last maternal injection.

STUDY DESIGN: Sixty-one women who received weekly injections of 17-OHPC underwent 2 pharmacokinetic studies at 20 + 0 to 24 + 6 weeks' gestation (study 1) and 31 + 0 to 34 + 6 weeks' gestation (study 2); daily blood samples were obtained between injections. In 18 women, blood samples were obtained over a 28-day period beyond the last injection (extended study). Maternal and/or cord blood were obtained at delivery.

English

Powered by Koha